Global Medical Device Trends: Lunit, FDA, and More
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Lunit has announced that its AI-powered breast cancer imaging tool is now used at over 330 sites across North America, coinciding with new FDA clearance for its 3D mammography features. Meanwhile, regulators and the industry are debating the separation of medical device manufacturing and product licenses. Additionally, a joint proposal by the U.S. CMS and FDA to fast-track Medicare coverage for innovative devices offers a significant strategic advantage for South Korean firms looking to enter the U.S. market.
Medical Device and Healthcare Industry Trends — 2026-04-24
Top 5 Headlines Today
- Lunit: Its AI breast cancer imaging solution is now adopted by over 330 screening sites in the U.S. and the Americas, with new FDA clearance granted for its updated 3D mammography tool.
- U.S. CMS/FDA: Jointly proposed an expedited Medicare coverage pathway for "Breakthrough" designated medical devices, potentially shortening the time for Korean export devices to enter the U.S. insurance market.
- MFDS (South Korea): Discussions are intensifying over the need to separate medical device manufacturing licenses from product licenses, with the definition of "subcontracting major processes" becoming a key issue.
- South Korean Medical Device Industry: Growing international interest in Korea's innovation and regulatory landscape, with an ongoing expansion in the designation of innovative devices utilizing AI and big data.
- FDA: Maintained its decision to reject the proposal for relaxing regulations on certain classes of AI medical devices, reaffirming its stance on maintaining strict oversight for high-risk AI medical tools.
Key Corporate Developments (4 Cases)
Lunit — Growth in U.S. AI Breast Imaging and New FDA Clearance
- What happened: Lunit revealed its adoption status in North America and announced it received new FDA clearance for its updated 3D Digital Breast Tomosynthesis (DBT) analysis tool.
- Key Metric: Deployment completed at over 330 screening sites across the U.S. and the Americas.
- Significance: This marks a milestone for a Korean AI medical device firm in achieving clinical adoption in the U.S. market. The new FDA clearance strengthens its portfolio and competitiveness, serving as a positive signal for future expansion into European and Asian markets.
South Korean Medical Device Industry — International Analysis
- What happened: The Italian certification body, Ente Certificazione Macchine, published a report analyzing the innovation and regulatory rigor of the Korean medical device market, labeling Korea a key global hub.
- Key Metric: 45 innovative medical device designations by the MFDS in 2025 (a 50% increase from the previous year), including AI and big data-based products.
- Significance: Recognition by a European certification body confirms the global credibility of Korea’s regulatory and innovation capabilities, favoring export diversification.
MFDS — Debate on Separating Licenses
- What happened: According to Hitnews, the industry is calling for the separation of manufacturing and product licenses. A major point of contention is the interpretation of the MFDS notification regarding the scope of "subcontracting major processes."
- Key Metric: The scope of application for Article 18-2 of the MFDS notification regarding subcontracting is the core issue.
- Significance: As contract manufacturing is common, the current licensing structure is viewed as a barrier to market entry. Easing these regulations would significantly increase operational flexibility for SMEs.
Global Pharma & Digital Health — $50 Million Investment in DTx
- What happened: According to the STAT News Health Tech newsletter, pharmaceutical companies invested $50 million in Digital Therapeutics (DTx), while the FDA maintained its refusal to relax regulations on certain AI devices.
- Key Metric: $50 million (approx. 68 billion KRW) invested in DTx.
- Significance: Increased investment from global pharma provides collaboration opportunities for Korean DTx developers. However, the FDA's stance means firms must remain focused on solid clinical evidence.
Policies and Regulations (3 Cases)
Debate on Licensing Separation
- Details: The industry is pushing to separate manufacturing and product licenses. The debate centers on whether the "subcontracting" regulation applies when only partial processes are outsourced.
- Impact: Improving clarity here could accelerate the time-to-market for domestic startups and SMEs.
MFDS Revision on Change Management (March 2026)
- Details: The MFDS is pushing for more flexible, systematic approaches to product change management through revisions to the Medical Device Enforcement Rules.
- Impact: Reduced burden for re-licensing after product changes will lower lifecycle management costs and align with global standards.
Market Immediate Entry Medical Technology System
- Details: Launched on January 26, 2026, by the Ministry of Health and Welfare and the MFDS, this system aims for clinical entry within 80 days.
- Impact: Faster market entry will help startups realize early revenue and boost investment in the domestic innovation ecosystem.
Global MedTech Context
- CMS/FDA Medicare Proposal: For Korean firms, this means that devices receiving "Breakthrough" designation may reach U.S. patients faster, accelerating monetization.
- FDA’s AI Stance: The rejection of regulatory relaxation for high-risk AI serves as a reminder to companies like Lunit and Vuno that clinical evidence requirements for the U.S. market remain high.
- FDA Wearable/Low-Risk Guidelines: Simplified regulations for low-risk software create a favorable environment for Korean wearable tech companies like Samsung and LG.
Today's Insight
Lunit’s success in moving from FDA clearance to active clinical adoption in over 330 sites marks a pivotal milestone for Korean AI medical tech. When combined with the proposed CMS/FDA expedited coverage pathway, Korean firms face a significant tailwind. Domestically, ongoing regulatory reforms regarding licensing and market entry are aligning to provide a smoother path for both local launches and international expansion.
Reader Action Items
- Professionals: Download the latest MFDS guidelines at and review the draft revisions regarding subcontracting.
- Investors: Re-evaluate valuations in the AI imaging sector, considering Lunit's adoption growth and its new 3D mammography FDA clearance.
- Founders: Review the requirements for the "Market Immediate Entry" system (80-day path) and simultaneously explore the U.S. FDA Breakthrough device designation for a dual-track strategy.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
